[144] ANAPTYSBIO, INC SEC Filing
ANAPTYSBIO, INC (ANAB) filed a Rule 144 notice regarding the proposed sale of 15,467 shares of common stock stemming from a stock option exercise dated May 21, 2026. The filing also disclosed two previous dispositions by Dennis Mulroy totaling 20,000 shares in mid-May 2026. This is a routine compliance filing, categorized as neutral in its impact and sentiment.
Wall Street analysts see a 38.75% upside in AnaptysBio (ANAB): Can the stock really move this high?
This article discusses the significant
AnaptysBio (NASDAQ: ANAB) moves fiscal year-end to June 30, 2026
AnaptysBio, Inc. (NASDAQ: ANAB) has announced a change to its fiscal year-end from December 31 to June 30, with the board of directors approving this on May 18, 2026. The new fiscal year will commence on July 1, 2026. The company will file a transition report, Form 10-KT, for the six-month period from January 1, 2026, through June 30, 2026, before beginning quarterly reports based on the new fiscal structure, starting with the quarter ending September 30, 2026.
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
AnaptysBio, Inc. (ANAB) is significantly outperforming the broader Medical sector this year, with a year-to-date return of 23.9% compared to the sector's average loss of 6.5%. The company, which holds a Zacks Rank #2 (Buy), also shows a strong positive trend in earnings estimates. Another top performer in the sector is Electromed, Inc. (ELMD), which has returned 29.6% year-to-date.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages
AnaptysBio, Inc. (NASDAQ:ANAB) has received an average "Moderate Buy" rating from thirteen brokerages, with a consensus one-year price target of $79.18. Analyst actions have been mixed, including an upgrade by Wedbush and price target adjustments by other firms, while Wall Street Zen downgraded the stock to "hold." The company recently reported a wider-than-expected quarterly loss but exceeded revenue estimates.
Dennis Mulroy (ANAB) files to sell 10,000 shares via option exercise
Dennis Mulroy, an insider at AnaptysBio, Inc. (ANAB), has filed a Form 144 to sell 10,000 shares of common stock, associated with a stock option exercise on May 19, 2026, with an aggregate value of $599,000. Morgan Stanley Smith Barney LLC is listed as the brokerage for this transaction. The filing also notes a prior sale of 10,000 shares on May 15, 2026, which yielded proceeds of $632,543.
AnaptysBio (NASDAQ:ANAB) Downgraded to "Hold" Rating by Wall Street Zen
AnaptysBio (NASDAQ:ANAB) was downgraded by Wall Street Zen from a "strong-buy" to a "hold" rating, despite other analysts maintaining a "Moderate Buy" consensus. The company reported a wider-than-expected quarterly loss of ($1.84) EPS but surpassed revenue estimates at $25.56 million. Shares were up 1.5% to $63.15, near its 50-day average, while insiders sold stock and institutional investors increased their holdings.
Point72 Group Holds 55,303 ANAB Shares (0.2%) — ANAB (ANAB)
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen collectively beneficially own 55,303 shares of ANAPTYSBIO, INC (ANAB), representing 0.2% of the common stock as of March 31, 2026. This ownership is reported via an amended Schedule 13G/A filing, indicating a passive investment where the shares are held through an investment fund managed by Point72 Asset Management. The filing clarifies that the reporting persons do not directly own these shares but hold shared voting and dispositive power through their investment management agreement.
[144] ANAPTYSBIO, INC SEC Filing
This SEC filing (Form 144) for ANAPTYSBIO, INC (ANAB) reports a proposed sale of 10,000 shares of common stock with an aggregate market value of $632,543.00. The shares were acquired through a stock option exercise on May 15, 2026, and are intended to be sold on NASDAQ. The filing indicates a neutral impact and sentiment.
Sirenia Capital discloses 1.92M shares of AnaptysBio (NASDAQ: ANAB)
Sirenia Capital Management and Alex Silverstein have jointly disclosed a 6.7% beneficial ownership stake in AnaptysBio (NASDAQ: ANAB), totaling 1,920,402 shares. This filing, a routine Schedule 13G, indicates shared voting and dispositive power over these shares, calculated against 28,748,255 shares outstanding as of February 27, 2026. The disclosure does not indicate any planned transactions.
Vanguard Group Inc. Increases Position in AnaptysBio, Inc. $ANAB
Vanguard Group Inc. has increased its stake in AnaptysBio, Inc. by 4.5% in the fourth quarter, bringing its total holdings to 1.54 million shares valued at approximately $74.9 million. This increase occurred despite AnaptysBio reporting a wider-than-expected quarterly loss of $1.84 per share, though revenue surpassed analyst estimates. Analysts maintain a "Moderate Buy" consensus for the stock with an average target price of $78.73, following several recent price target increases.
HighMark Wealth Management LLC Has $4.56 Million Position in AnaptysBio, Inc. $ANAB
HighMark Wealth Management LLC reduced its stake in AnaptysBio, Inc. (ANAB) by 30.4% in the fourth quarter, yet still holds 94,050 shares valued at approximately $4.56 million, making it their 11th largest holding. Despite a recent wider-than-expected quarterly loss, analysts generally maintain a "Moderate Buy" consensus rating with a target price of $78.73. Insider selling by the CEO and a director was also reported, though the company authorized a significant share repurchase program.
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $70.54, Implies 8% Upside
AnaptysBio, Inc.'s average 12-month stock price target has been increased from $68 to $70.54 by 11 analysts, with forecasts ranging from $43.99 to $93.32 per share. This updated target suggests an approximate 8% potential upside based on the closing price of May 12. The consensus rating for AnaptysBio, Inc. remains a "Buy" across all covering analysts.
AnaptysBio (NASDAQ: ANAB) grants CFO 25,765 restricted stock units
AnaptysBio (NASDAQ: ANAB) has granted its Chief Financial Officer, Christopher M. Murphy, 25,765 restricted stock units (RSUs). These RSUs represent a contingent right to receive one share of common stock each for no cash consideration. The units will vest in four equal annual installments of 25%, beginning on May 11, 2027, provided Murphy remains employed by the company.
AnaptysBio (NASDAQ: ANAB) director Hughes Owen files initial Form 3 insider report
AnaptysBio director Hughes Owen has filed an initial Form 3 insider ownership report, establishing his status as a company insider under SEC rules. The filing, which shows no buy, sell, or derivative transactions, indicates that Owen is now subject to Section 16 reporting obligations. This initial report does not detail any stock holdings but signifies his official connection as a director of ANAPTYSBIO, INC.
UBS Adjusts Price Target on AnaptysBio to $76 From $70, Maintains Buy Rating
UBS has increased its price target for AnaptysBio from $70 to $76 while reaffirming a Buy rating. The article also includes information about Unity Software's fourth-quarter financial results, noting higher-than-expected revenue and a quarterly loss per share.
AnaptysBio (NASDAQ:ANAB) Trading Down 7.7% After Earnings Miss
AnaptysBio (NASDAQ:ANAB) shares dropped 7.7% after the company reported an earnings per share miss of ($1.84) against a consensus of ($0.64) for the quarter. Despite the earnings shortfall, the biotechnology company exceeded revenue expectations, bringing in $25.56 million compared to analyst estimates of $18.86 million. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $78.73, while recent insider transactions show some sales.
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $69.09, Implies 5% Upside
AnaptysBio, Inc. (ANAB) stock's average 12-month price target has been increased from $68 to $69.09 by 11 analysts, implying a 5% potential upside based on its May 12 closing price. The consensus rating for ANAB remains a "Buy," with all 11 covering analysts recommending it. This update suggests continued analyst confidence in the stock's future performance.
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75
TD Cowen has reaffirmed its Buy rating for AnaptysBio (ANAB.US) and maintained its target price of $75. This indicates a continued positive outlook from the firm regarding the company's stock performance.
AnaptysBio Appoints New CFO and Board Director
AnaptysBio has announced the appointment of Christopher M. Murphy as its new Chief Financial Officer, formalizing his role with a consulting agreement that includes performance-based compensation and a significant equity grant. Additionally, the company expanded its board by appointing Owen Hughes as a Class I director. These appointments reflect AnaptysBio's focus on independent oversight and strengthening its leadership as it enters a potentially transformative phase.
AnaptysBio, Inc. (ANAB) Misses Q1 EPS by 88c
AnaptysBio, Inc. (ANAB) reported its Q1 earnings, with an EPS of ($1.84), missing the analyst estimate of ($0.96) by $0.88. Despite this, the company's revenue for the quarter was $25.56 million, exceeding the consensus estimate of $23.04 million. Investors can access the company's earnings history and related data for more details.
AnaptysBio (NASDAQ:ANAB) Releases Earnings Results, Misses Expectations By $1.20 EPS
AnaptysBio (NASDAQ:ANAB) reported Q1 earnings of ($1.84) EPS, significantly missing analyst estimates of ($0.64) by $1.20, despite revenue of $25.56 million surpassing expectations. The stock consequently dropped 3.4% in mid-day trading to $65.58, though it remains near its 52-week high. Analysts largely maintain a "Moderate Buy" rating with an average price target of $76.18, even as notable insider sales have occurred recently.
[8-K] ANAPTYSBIO, INC Reports Material Event
AnaptysBio, Inc. (ANAB) filed an 8-K report announcing its financial results for the first quarter ended March 31, 2026, and provided a business update. The company reported a net loss of $52.9 million for the quarter, or $1.84 per share, and detailed its financial collaborations for Jemperli with GSK and imsidolimab with Vanda. AnaptysBio also announced recent leadership appointments, including Chris Murphy as CFO, and updates on its stock repurchase plan.
Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q1 Revenue $25.6M, vs. FactSet Est of $18.9M
AnaptysBio, Inc. (ANAB) announced Q1 revenue of $25.6 million, significantly exceeding FactSet's estimate of $18.9 million. The company's stock was trading at $65.58, showing a 5-day change of -3.45%, a January 1st change of -6.02%, and a 35.27% increase year-to-date. Recent news also includes executive appointments and favorable rulings in intellectual property disputes.
AnaptysBio names Christopher Murphy CFO, adds Owen Hughes to board By Investing.com
AnaptysBio, Inc. (NASDAQ:ANAB) announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes to its board of directors. The biotech company has seen significant stock growth, with analysts projecting profitability this year. These appointments coincide with recent strategic shifts, including the spin-off of biopharma operations and a favorable court decision regarding royalty rates.
AnaptysBio appoints Christopher M. Murphy as CFO; Owen Hughes joins board
AnaptysBio announced the appointment of Christopher M. Murphy as Chief Financial Officer and Owen Hughes as a Class I director, both effective May 11, 2026. Murphy previously served as CFO at Third Harmonic Bio, while Hughes received a grant of restricted stock units. These appointments were detailed in an SEC filing.
New CFO and director join AnaptysBio (NASDAQ: ANAB) with equity grants
AnaptysBio, Inc. (NASDAQ: ANAB) has appointed Christopher M. Murphy as its new Chief Financial Officer, effective May 11, 2026. Murphy will serve as an independent contractor, receiving monthly consulting fees, an annual cash bonus opportunity, and an equity grant valued at $1,750,000 in restricted stock units. Additionally, Owen Hughes was appointed as a Class I director, also effective May 11, 2026, and received an initial grant of 11,250 restricted stock units.
AnaptysBio names Christopher Murphy CFO, adds Owen Hughes to board
AnaptysBio, Inc. (NASDAQ:ANAB) has appointed Christopher Murphy as its new Chief Financial Officer and Owen Hughes to its board of directors. The biotech company, which has seen its stock surge 431% over the past year, is expected to become profitable this year according to analyst forecasts. These appointments come after AnaptysBio completed the spin-off of its biopharma operations to focus on managing royalty streams.
AnaptysBio Appoints Chris Murphy as CFO, Owen Hughes to Board
AnaptysBio has announced the appointment of Chris Murphy as its new Chief Financial Officer. Additionally, Owen Hughes has been appointed to the company's Board of Directors. These strategic leadership changes aim to strengthen AnaptysBio's financial and governance functions.
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio, Inc. has announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes to its Board of Directors. These appointments aim to strengthen the company's leadership team and board with additional expertise in business development, finance, and royalty management. The company highlighted that these additions will help Anaptys focus on protecting and returning the value of its royalty assets to shareholders.
10 Best Performing Healthcare Stocks So Far in 2026
This article highlights AnaptysBio, Inc. (NASDAQ:ANAB) as one of the top-performing healthcare stocks in 2026, with a YTD share price gain of 131.2%. The company recently completed a spin-off, focusing on royalty management, and had a breach of contract claim dismissed in its favor. Piper Sandler reaffirmed an "Overweight" rating on ANAB shares, although the article also suggests that some AI stocks may offer greater promise.
AnaptysBio earnings up next: First report as royalty company
AnaptysBio is set to report its first-quarter earnings, marking its debut as a pure-play royalty management company after spinning off its biopharma operations. The company will focus on managing financial collaborations for GSK's Jemperli and Vanda Pharmaceuticals' imsidolimab. Analysts anticipate a loss of $0.96 per share and $23.04 million in revenue, a significant decrease from the previous quarter, as the company transitions to a high-margin royalty model with minimal operating expenses.
AnaptysBio earnings up next: First report as royalty company
AnaptysBio Inc. is preparing to report its first-quarter earnings, marking its debut as a pure-play royalty management company after spinning off its biopharma operations. The company will focus on managing financial collaborations for GSK’s Jemperli and Vanda Pharmaceuticals’ imsidolimab. Analysts anticipate a loss of $0.96 per share on revenues of $23.04 million, as the company targets a high EBIT margin with its new virtual model.
AnaptysBio earnings up next: First report as royalty company
AnaptysBio is set to report its first-quarter earnings as a pure-play royalty management company after spinning off its biopharma operations. Analysts anticipate a loss of $0.96 per share on $23.04 million in revenue, a significant decline from the previous quarter which included its former biopharma business. The market will be watching to see if the company can demonstrate its high-margin royalty revenue model, particularly with the performance of GSK's Jemperli and the potential FDA approval for Vanda Pharmaceuticals' imsidolimab.
AnaptysBio, Inc. (ANAB) is a great momentum stock: Should you buy?
This article evaluates AnaptysBio, Inc. (ANAB) as a momentum stock. It suggests that momentum investors might find ANAB appealing due to its strong short-term performance, indicated by factors like the 50-day moving average and positive earnings estimate revisions. However, without more detailed content, a definitive recommendation cannot be made.
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
AnaptysBio, Inc. (ANAB) is identified as a strong momentum stock with a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of A. The article highlights ANAB's recent positive price performance, outperforming its industry and the S&P 500 over the past week, month, quarter, and year. Additionally, positive earnings estimate revisions further support its strong momentum and potential for market outperformance.
AnaptysBio (NASDAQ:ANAB) Upgraded to Strong-Buy at Zacks Research
Zacks Research has upgraded AnaptysBio (NASDAQ:ANAB) from a "hold" to a "strong-buy" rating. This upgrade comes amidst varying analyst opinions, with a consensus "Moderate Buy" rating and an average target price of $76.18. The article also details the company's recent price performance, earnings, and insider trading activities.
ANAB Maintained by Piper Sandler -- Price Target Lowered to $93
Piper Sandler has maintained an "Overweight" rating on AnaptysBio (ANAB) but lowered its price target from $95.00 to $93.00, reflecting a cautious outlook despite the company being significantly undervalued by 51.5% according to GuruFocus's GF Value™. Insider activity shows $2.8 million in sales over the last three months with no purchases, indicating a potential cautious sentiment. AnaptysBio, a clinical-stage biotechnology company, is focused on developing antibody product candidates for inflammation and immuno-oncology, with several therapies in clinical trials.
AnaptysBio CEO to appear at royalty company virtual conference
AnaptysBio (Nasdaq: ANAB) announced that its President and CEO, Daniel Faga, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026, at 1:30 PM ET. The discussion will focus on the company's financial collaborations for Jemperli and imsidolimab. This announcement comes after a period of significant strategic changes and clinical validation for AnaptysBio.
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
AnaptysBio, Inc. (Nasdaq: ANAB) announced that its president and CEO, Daniel Faga, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026, at 1:30 PM ET. The company focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to protect and return royalty value to shareholders.
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
AnaptysBio, Inc. announced that Daniel Faga, president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026, at 1:30 PM ET. The company focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to protect and return royalty value to shareholders.
Piper Sandler Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price
Piper Sandler has reiterated an "overweight" rating on AnaptysBio (NASDAQ:ANAB) but slightly lowered its price target from $95 to $93, projecting a 33.9% upside. Despite the optimistic rating, the biotechnology company faces challenges as it remains unprofitable with negative ROE, and analysts expect a negative EPS of -3.15 for the current fiscal year. Insider selling of approximately $2.79 million in stock has also been noted.
Director Susannah Gray receives 11,250 RSUs at AnaptysBio (ANAB)
AnaptysBio director Susannah Gray has been granted 11,250 Restricted Stock Units (RSUs) as part of her compensation. Each RSU represents a contingent right to receive one common stock share without cash consideration upon settlement. The RSUs will vest in installments, with one-third vesting on April 27, 2027, and the remaining in equal annual installments, subject to her continued service.
AnaptysBio, Inc. (ANAB) may report negative earnings: Know the trend ahead of Q1 release
This article forecasts that AnaptysBio, Inc. (ANAB) is likely to report negative earnings for its upcoming Q1 release, based on the Zacks Consensus Estimate of a loss of $0.62 per share. The company's EPS surprise history indicates a recent trend of exceeding estimates, however, its Zacks Rank #3 (Hold) combined with a negative Earnings ESP suggests a higher probability of missing current estimates. Investors are advised to consider these details alongside the expected revenue of $29.7 million for Q1.
ANAB SEC Filings - Anaptysbio Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Anaptysbio (ANAB) SEC filings, including annual 10-K, quarterly 10-Q, material event 8-K reports, and insider trading forms. It features AI-powered summaries of these documents to aid investors in understanding regulatory disclosures, strategic decisions, and financial updates. Recent filings detail stock sales by directors for tax purposes and the company's litigation against Tesaro and GSK.
Fenwick Secures Chancery Court Victory for AnaptysBio in Licensing Dispute
Fenwick successfully represented AnaptysBio in a significant Delaware Chancery Court case, preserving AnaptysBio's royalty rights against Tesaro, Inc. (a GlaxoSmithKline subsidiary). The dispute involved a collaboration and exclusive license agreement for the cancer therapy Jemperli, where Tesaro attempted to reduce royalty payments. The court dismissed Tesaro's claims of anticipatory breach, affirming Fenwick's expertise in complex life sciences licensing disputes.
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year High - Time to Buy?
AnaptysBio (NASDAQ:ANAB) recently reached a new 52-week high of $70.22, closing at $66.59, and saw a significant trading volume. Analysts generally rate the stock a "Moderate Buy" with an average price target of $75.50, despite mixed recent target revisions. The company reported better-than-expected quarterly earnings but remains unprofitable, and insiders have sold shares totaling approximately $2.79 million.
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) shares surged 14.8% after a Delaware court dismissed a breach of contract claim against the company, preserving existing royalty rates for its drug Jemperli. Despite this positive legal outcome, the company faces a negative trend in earnings estimate revisions for its upcoming report, with revenues expected to decline. Investors are advised to monitor ANAB's performance to see if the recent jump translates into sustained gains.
GSK (NYSE: GSK) outlines TESARO–AnaptysBio dostarlimab litigation status and Jemperli growth
GSK announced a procedural update regarding its lawsuit with AnaptysBio concerning the cancer drug dostarlimab (Jemperli). A Delaware court dismissed TESARO's claim for anticipatory breach, but GSK clarifies that this ruling does not address the core contractual dispute, and TESARO will pursue its remaining claim for declaratory judgment. GSK also highlighted significant growth for Jemperli due to label expansions and ongoing clinical trials for other cancer types.
GSK Subsidiary TESARO Faces Setback in AnaptysBio Litigation, Jemperli Growth Remains Strong
GSK subsidiary TESARO has announced a setback in its legal dispute with AnaptysBio, Inc., as the Delaware Chancery Court granted AnaptysBio's motion to dismiss TESARO's claim for anticipatory breach. Despite this, TESARO and GSK maintain that AnaptysBio's allegations are without merit and will continue to pursue their remaining claim. Concurrently, Jemperli (dostarlimab), TESARO's drug at the center of the dispute, continues to show strong growth driven by label expansions and ongoing clinical trials for additional cancer types.
